Introduction {#Sec1}
============

Molecular imaging is a technique that is focused on the non-invasive assessment of in vivo molecular and associated physiological processes. The most established modalities used for molecular imaging are single photon emission computed tomography (SPECT) and positron emission tomography (PET), which use radiotracers that are capable of targeting specific biological events associated with disease progression and therapeutic success. Both SPECT and PET possess high sensitivity and good tissue penetration depth, making them ideal modalities for targeted molecular imaging. The development of hybrid imaging systems in recent years now permits co-localization of high-sensitivity functional SPECT and PET images with high-spatial resolution anatomical images from X-ray computed tomography (CT) and magnetic resonance (MR) systems. These hybrid systems allow for attenuation correction and partial volume correction, thereby improving localization and quantification of radiotracer uptake within specific anatomical regions of interest (e.g., organ systems, soft tissue, vascular networks) \[[@CR1]\].

The most established modality for molecular imaging is PET; however, SPECT imaging offers some advantages. SPECT cameras are less expensive and more widely available compared to PET systems. SPECT systems allow for the routine use of dual radioisotope imaging through the differentiation of gamma emitters, thus permitting simultaneous imaging of molecular and physiological indices, such as angiogenesis and tissue perfusion. The use of PET systems continues to grow due to increased availability of hybrid systems with higher sensitivity for detection of molecular events and higher spatial resolution imaging than traditional SPECT systems. Additionally, PET imaging commonly incorporates radiotracers with shorter half-lives, which ultimately results in decreased patient exposure to ionizing radiation \[[@CR2]\]. Recent pre-clinical work suggests the possibility of dual-isotope PET imaging using pure positron emitters (e.g., nitrogen-13, fluorine-18) and radiotracers that emit a prompt gamma (e.g., rubidium-82, bromine-76, iodine-124) in association with the primary beta, allowing newer PET systems with faster electronics and shorter detector decay constants the ability to detect coincidences and triplets \[[@CR3], [@CR4]\].

One physiological process of significant interest in the medical community that may be better evaluated through the use of radiotracer-based molecular imaging is angiogenesis, a process that plays an important role in the restoration of tissue perfusion and blood flow following the onset of myocardial and skeletal muscle ischemia \[[@CR5]\]. Traditional assessment of angiogenesis has been restricted to postmortem histological analyses that require the killing of large numbers of animals to validate quantitative findings, thus increasing research costs and decreasing clinical relevance of therapies targeted at promoting or hindering the process of angiogenesis. Further development of molecular imaging approaches should facilitate the translation of novel therapeutics into clinical trials and improve patient management by permitting non-invasive assessment of serial angiogenic responses to treatment.

Angiogenesis {#Sec2}
============

Angiogenesis, in general, is the physiological process by which new capillaries are formed from pre-existing vessels. Formation of new microvascular networks can be of critical significance in the setting of cardiovascular disease, as angiogenesis can assist in restoring blood flow and perfusion to skeletal muscle or cardiac tissue exposed to hypoxic conditions and potentially prevent the onset of tissue necrosis. Angiogenesis is regulated through multiple angiogenic factors, cells, and the extracellular matrix (ECM), and can be stimulated in the setting of various conditions that may be associated with cardiovascular disease, such as ischemia, hypoxia, inflammation, and alterations in vascular shear stress \[[@CR5]\]. The process of angiogenesis can be described by several stages. These stages are first characterized by the initial activation of endothelial cells that leads to increased permeability and proliferation of endothelial cells. Next, the extracellular matrix (ECM) is degraded, with the assistance of multiple factors such as matrix metalloproteinases (MMPs) and integrins, which facilitates infiltration of endothelial cells. Following ECM breakdown and endothelial cell migration, the development and eventual stabilization of a new capillary occurs \[[@CR6]\].

Numerous factors have been attributed to stimulating angiogenesis in the setting of tissue hypoxia, such as hypoxia-inducible factor 1 (HIF-1), vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), fibroblast growth factor-2 (FGF-2), transforming growth factor beta (TGF-β), and angiopoietins \[[@CR7]--[@CR10]\]. With the assistance of the aforementioned angiogenic mediators, additional signaling events result in participation of endothelial cells, vascular smooth muscle cells, blood-derived macrophages, and circulating stem cells in the angiogenic process \[[@CR11]\]. In addition to macrophages, a variety of other inflammatory cells and mediators can play important roles in angiogenesis. Through hypoxia-induced stimulation, inflammatory cells can release multiple angiogenesis-stimulating factors and proteases, such as vascular endothelial growth factor (VEGF), tumor necrosis factor-α (TNF-α), cytokines, and MMPs. Inflammatory cells can also release reactive oxygen species (ROS), which can serve as stimulators of the angiogenic process \[[@CR6]\].

While there are many known mediators of the angiogenic process, VEGF has been established as one of the most influential contributors to vascular development. Five VEGF-related growth factors exist, which stimulate angiogenesis through binding to three tyrosine kinase receptors (VEGFR-1, VEGR-2, and VEGR-3) \[[@CR12]\]. Along with VEGF's established role, integrins are also considered to be important regulators of the angiogenic process. These transmembrane receptors are capable of mediating cell-to-cell and cell-to-ECM interactions and can modulate cell adhesion, migration, proliferation, differentiation, and survival. The αvβ3 integrin has been of particular interest due to significant involvement in the regulation of cell interactions with the ECM and endothelial cell migration \[[@CR13]\]. As the field of molecular imaging continues to develop, VEGF and the αvβ3 integrin have emerged as the primary targets for non-invasive evaluation of cardiovascular-related angiogenesis; however, multiple targets are currently available for the evaluation of angiogenesis in the setting of cancer, cardiovascular disease, and inflammation. Established targets for molecular imaging of angiogenesis have been grouped into three categories: 1) non-endothelial cell targets (e.g., monocytes, macrophages, and stem cells), endothelial cell targets (e.g., VEGF, receptors, and integrins), and 3) ECM proteins and proteases \[[@CR5]\]. Future discussion will be limited to translational cardiovascular imaging approaches that have been performed for the non-invasive assessment of myocardial and peripheral angiogenesis.

Radiotracer imaging of myocardial angiogenesis {#Sec3}
==============================================

Angiogenesis is enhanced in the setting of myocardial ischemia as a physiological response to ischemic insult, particularly in the setting of myocardial infarction (MI). In animal models of MI, angiogenic activation after MI can be confirmed by histopathologic analysis, such as capillary density measurement. However, non-invasive imaging is currently the only practical method for evaluating angiogenesis in vivo. Many studies have reported augmented angiogenesis following MI as well as cerebral infarction by using radiotracer imaging methods \[[@CR14], [@CR15]\]. Among radiotracer-based studies targeted at the angiogenic process, the RGD peptide (composed of [l]{.smallcaps}-arginine, glycine, and [l]{.smallcaps}-aspartic acid) moiety targeted at the integrin αvβ3 has been most widely applied. The αvβ3 integrin is expressed on the surface of the endothelium that is activated for angiogenesis. Additionally, the expression of αvβ3 integrin is present on activated macrophages. Thus, the RGD peptide moiety targets for both post-infarct angiogenesis and macrophage accumulation. The uptake of RGD peptide agents in the post-infarct myocardium has been demonstrated to be closely related to expression of CD31 (angiogenesis marker) and CD68 (macrophage marker), as well as integrin expression \[[@CR16]--[@CR20]\].

Many studies have reported visualization and quantification of increased angiogenesis following MI using radiotracer-based imaging approaches. Early application of radiotracer-based imaging for the evaluation of post-MI angiogenesis was performed using scintigraphy or single photon emission computed tomography (SPECT). SPECT imaging with indium-111 (^111^In)-RP748 in rat and canine models of MI have demonstrated a 2- to 4-fold increase in myocardial uptake within infarcted myocardium compared to remote regions \[[@CR16], [@CR21], [@CR22]\]. Technetium-99 m (^99m^Tc) is currently a more readily accessible radioisotope than ^111^In, and studies using ^99m^Tc-labeled RGD peptides (^99m^Tc-RAFT-RGD and ^99m^Tc-NC100692) have shown increased accumulation of these radiotracers within infarcted myocardium and the border zone of infarction (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR17], [@CR23]\]. PET imaging has become more widely available for pre-clinical and clinical imaging, and angiogenesis-targeted radiotracers for PET have been investigated more extensively than radiotracers for gamma cameras. Flourine-18 (^18^F)-galacto-RGD \[[@CR24], [@CR25]\], copper-64 (^64^Cu)-VEGF \[[@CR26]\], ^18^F-PRGD \[[@CR18]\], ^64^Cu-TRC105 \[[@CR27]\], and several gallium-68 (^68^Ga)-labeled RGD peptide agents \[[@CR19], [@CR20], [@CR28], [@CR29]\] have been reported to be effective for PET imaging of post-infarct angiogenesis (Table [1](#Tab1){ref-type="table"}). Pre-clinical PET studies in animal models of MI have demonstrated a 1.5- to 3.9-fold increase in angiogenesis activity from baseline levels within infarcted myocardium \[[@CR18]--[@CR20], [@CR27]\]. In addition to pre-clinical application, some PET angiogenesis-targeted tracers have reached the clinical setting for the assessment of post-MI remodeling and have demonstrated approximately a 2-fold increase in radiotracer uptake within infarcted myocardium when compared to normal or remote myocardium \[[@CR25], [@CR28]\].Fig. 1SPECT imaging of myocardial angiogenesis in a canine model of myocardial infarction obtained 2 weeks following 6 h balloon occlusion of the left anterior descending artery. Focal uptake of ^99m^Tc-NC100692 is observed in the region of myocardial infarction (denoted by *white arrow*), which is localized to a region of decreased perfusion, as identified by ^201^Tl SPECT (*yellow arrow*) (color figure online)Table 1Radiotracers for imaging of cardiovascular angiogenesisBiologic targetRadiotracerModalityMyocardial Pre-clinical^64^Cu-DOTA-VEGF~121~ \[[@CR26]\]PET^64^Cu-NOTA-TRC105 \[[@CR27]\]PET^18^F-Galacto-RGD \[[@CR24], [@CR29]\]PET^68^Ga-NOTA-RGD \[[@CR19], [@CR20]\]PET^68^Ga-PRGD2 \[[@CR28]\]PET^68^Ga-NODAGA-RGD \[[@CR29]\]PET^68^Ga-TRAP(RGD)~3~ \[[@CR29]\]PET^18^F-AIF-NOTA-PRGD2 \[[@CR18]\]PET^123^I-Gluco-RGD \[[@CR30]\]SPECT^99m^Tc-NC100692 \[[@CR31], [@CR44], [@CR45]\]SPECT^99m^Tc-RAFT-RGD \[[@CR17]\]SPECT^111^In-RP748 \[[@CR16], [@CR21], [@CR22]\]SPECT Clinical trials^18^F-Galacto-RGD \[[@CR25]\]PET^99m^Tc-NC100692 \[[@CR33]\]SPECTPeripheral^76^Br-nanoprobe \[[@CR35]\]PET^68^Ga-NOTA-RGD \[[@CR41]\]PET^64^Cu-DOTA-CANF-comb \[[@CR43]\]PET^64^Cu-DOTA-VEGF~121~ \[[@CR42]\]PET^64^Cu-NOTA-TRC105 \[[@CR34], [@CR46]\]PET^99m^Tc-NC100692 \[[@CR36], [@CR40], [@CR47], [@CR48]\]SPECT^111^In-VEGF~121~ \[[@CR37]\]SPECT^125^I-c(RGD(I)yV) \[[@CR39]\]SPECT

The natural time course of post-infarct remodeling can be serially evaluated using non-invasive angiogenesis-targeted imaging. Despite differences that exist in the animal models studied and the radiotracers incorporated, increased angiogenesis (as assessed by αvβ3 integrin activation) has commonly been observed within 1--3 days after occurrence of MI \[[@CR16], [@CR22], [@CR24], [@CR25]\]. In the majority of studies, myocardial uptake of radiotracers reached peak levels at 1--3 weeks following infarction \[[@CR18], [@CR23], [@CR24], [@CR28]\]. However, considerable variation in the persistence of angiogenesis signal has been demonstrated, with some studies reporting that radiotracer uptake is normalized as early as 17 days following infarction \[[@CR27]\], whereas other studies report persistent uptake for up to 4--6 months \[[@CR18], [@CR24]\]. Work in our own laboratory has demonstrated normalization of the angiogenic response at approximately 6--9 weeks following MI in a canine model of temporary left anterior descending artery (LAD) occlusion \[[@CR23]\]. The differences in the time courses for angiogenesis that have been observed following MI may be related to a number of variables, including the animal model being utilized and the duration and site of coronary occlusion.

In recent years, therapeutic angiogenesis using various growth factors and gene- or cell-based therapies have been attempted to induce angiogenesis and relieve myocardial ischemia. Pre-clinical application of SPECT and PET imaging has demonstrated that radiotracer-based imaging of angiogenesis may be useful for monitoring the effect of therapeutic treatments. In a swine model of hibernating myocardium, focal uptake of iodine-123 (^123^I)-gluco-RGD was found to correspond with sites of prior intra-myocardial VEFG injections and correlated with postmortem analysis of capillary density \[[@CR30]\]. In addition to the use of ^123^I-gluco-RGD for monitoring of VEGF therapy in infarcted myocardium, ^99m^Tc-RAFT-RGD SPECT and ^68^Ga-NOTA-RGD PET imaging have also been used to evaluate VEGF and fibroblast growth factor therapies in rat models of MI \[[@CR19], [@CR30]\]. In these studies, radiotracer uptake was observed in accordance with increased capillary density and other markers of angiogenesis. Other pre-clinical work using micro-SPECT/CT imaging of ^99m^Tc-NC100692 has demonstrated potential for evaluating the angiogenic response to insulin-like growth factor-1 gene therapy in a rat model of MI, suggesting that monitoring of therapeutic efficacy with angiogenesis imaging could have potential for clinical application \[[@CR31]\].

Molecular imaging of myocardial angiogenesis has been translated to the clinical setting for the evaluation of patients with hypertrophic cardiomyopathy \[[@CR32]\] and heart failure \[[@CR33]\], as well as following acute MI \[[@CR25]\]. In the evaluation of acute MI, focal uptake of ^18^F-galacto-RGD has been shown to localize to the MI area defined by delayed enhancement magnetic resonance (MR) imaging \[[@CR25]\]. The use of ^99m^Tc-NC100692 in patients with hypertrophic cardiomyopathy has also demonstrated higher-grade radiotracer uptake within regions of fibrosis detected by MR \[[@CR32]\]. Additionally, ^99m^Tc-NC100692 has been used to evaluate the therapeutic efficacy of bone marrow-derived stem cell therapy in patients with heart failure; however, radiotracer uptake was found to be only mildly correlated with functional improvement \[[@CR33]\]. Further investigation into the long-term prognostic role of monitoring the angiogenesis process in the setting of hypertrophic heart disease, following MI, or in the evaluation of therapeutic treatments is warranted, while the context of clinical conditions should also be considered in the interpretation of molecular imaging strategies.

Radiotracer imaging of peripheral angiogenesis {#Sec4}
==============================================

In addition to being a useful tool for non-invasive assessment of myocardial ischemia, molecular imaging of angiogenesis has also proven to be effective in the evaluation of limb ischemia. Ischemia-induced angiogenesis has been demonstrated to occur in various pre-clinical models of femoral artery occlusion, such as rodent \[[@CR34]--[@CR36]\], rabbit \[[@CR37]\], and pig models \[[@CR38]\]. Although molecular imaging of peripheral angiogenesis has not yet reached clinical application, pre-clinical work has shown promising results for non-invasive serial analysis of the angiogenic process, with the primary vascular targets of choice being VEGF receptors and the αvβ3 integrin.

In one of the first molecular imaging studies targeting peripheral angiogenesis, Lu et al. \[[@CR37]\] targeted VEGF receptors in a rabbit model of unilateral hind limb ischemia using planar imaging and gamma counting of ^111^In-labeled recombinant human VEGF~121~. Ten days following surgically induced limb ischemia, both imaging and gamma counting demonstrated increased uptake of ^111^In-labeled VEGF~121~ in ischemic vs. control hind limb tissue. Furthermore, immunohistochemical analysis of ischemic tissue confirmed an increase in VEGF receptor expression.

Along with targeting of VEGF receptors, early work in mouse models of hind limb ischemia also targeted the αvβ3 integrin using iodine-125 (^125^I)- and ^99m^Tc-labeled RGD peptides \[[@CR39], [@CR40]\]. Lee et al. \[[@CR39]\] evaluated ^125^I-c(RGD(I)yV uptake in ischemic hind limb tissue using gamma counting and found significantly increased radiotracer uptake at days 3, 8, and 14 following femoral ablation, which was also associated with gradual recovery of limb perfusion (evaluated by laser Doppler). Additionally, radiotracer uptake was validated through immunohistochemistry that demonstrated a pronounced increase in αvβ3 integrin expression in ischemic tissue. Further evaluation of serial changes in αvβ3 integrin expression during the angiogenic process has been performed in the ischemic hind limb through non-invasive in vivo planar imaging of ^99m^Tc-NC100692 \[[@CR40]\]. Imaging demonstrated radiotracer uptake in the distal hind limb that increased at 3 days and peaked at 7 days following femoral artery occlusion. Image quantification was validated by gamma counting of hind limb tissue, and increased radiotracer uptake corresponded with serial increases in capillary density. Additionally, immunofluorescent staining confirmed specificity and co-localization of NC100692 (targeting the αvβ3 integrin) to endothelial cells. Further work has validated and applied a semiautomated quantitative approach for serial micro-SPECT/CT imaging of ^99m^Tc-NC100692 and demonstrated high reproducibility and accuracy of this approach for evaluating angiogenesis within specific volumes of interest in the hind limbs of wild-type and endothelial nitric oxide synthase (eNOS) knockout mice \[[@CR36]\]. Peak ^99m^Tc-NC100692 uptake was found to occur 1 week following femoral artery occlusion in both wild-type and eNOS knockout mice; however, there was a significant decrease in radiotracer uptake in eNOS-deficient mice relative to wild-type mice at the 1 week post-occlusion time point. These results suggest that SPECT/CT imaging of angiogenesis may be a useful non-invasive tool for future translational studies evaluating different stages and forms of disease, such as peripheral vascular disease and diabetes. Work from our laboratory has recently focused on translating ^99m^Tc-NC100692 SPECT/CT imaging from a small to large animal model of hind limb ischemia to non-invasively evaluate serial changes in angiogenesis and has demonstrated focal radiotracer uptake within ischemic tissue and surgical site (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Serial imaging of angiogenesis in a pig model of hind limb ischemia. Fused ^99m^Tc-NC100692 SPECT and CT axial images at 2 (**a**) and 4 (**b**) weeks post-femoral artery occlusion demonstrate focal uptake of ^99m^Tc-NC100692 in the lateral aspect of the hind limb (*white arrows*), as well as in the surgical site (*yellow arrows*) (color figure online)

In addition to ^111^In and ^99m^Tc labeling of angiogenesis-targeted compounds, ^68^Ga \[[@CR41]\] and ^64^Cu \[[@CR42]\] have also been used for non-invasive assessment of angiogenesis in the mouse model of hind limb ischemia. In a feasibility study by Jeong et al. \[[@CR41]\], ^68^Ga-NOTA-RGD targeted at the αvβ3 integrin demonstrated specific uptake by angiogenic hind limb tissue, high stability, high affinity for the αvβ3 integrin, and good pharmacokinetic properties. In another study utilizing micro-PET imaging of ^64^Cu-VEGF~121~, radiotracer uptake was significantly increased in ischemic hind limb tissue 8 days following femoral artery ligation and subsequently displayed a steady decrease in uptake over the following 3 weeks \[[@CR42]\]. Interestingly, ^64^Cu-VEGF~121~ uptake was also significantly higher in the skeletal muscle of mice exposed to hind limb ischemia and exercise training when compared to non-exercised controls, with radiotracer uptake being strongly correlated with VEGFR2 tissue levels.

^64^Cu has also been used for labeling of C-type atrial natriuretic factor (CANF)-conjugated comblike nanoprobes for detecting the upregulation of natriuretic peptide clearance receptor (NPR-C) in the setting of hind limb ischemia \[[@CR43]\]. PET imaging of targeted ^64^Cu-DOTA-CANF-comb demonstrated a nearly 6-fold increase in radiotracer uptake at 24 h post-femoral artery ligation in the ischemic hind limb relative to the non-ischemic control limb, which corresponded with gradual recovery of blood flow, indicative of a progressive angiogenic response. Immunohistochemistry established co-localization of NPR-C in endothelial and smooth muscle cells, and specificity of ^64^Cu-DOTA-CANF-comb to NPR-C was demonstrated via competitive receptor blocking. In addition to ^64^Cu-labeled nanoprobes, Almutairi et al. developed biodegradable dendritic nanoprobes that were functionalized with heterobifunctional polyethylene oxide (PEO) chains and used for targeted PET imaging of the αvβ3 integrin in hind limb angiogenesis \[[@CR35]\]. PEO chains were fitted with RGD motifs for selective targeting of the αvβ3 integrin. Labeling of nanoprobes with ^125^I for cell-based assays demonstrated a 6-fold increase in nanoprobe uptake within αvβ3-positive cells. Additionally, in vivo PET imaging of bromine-76 (^76^Br)-labeled nanoprobes confirmed specific uptake within angiogenic hind limb tissue.

Most recently, ^64^Cu-labeleling of NOTA-conjugated TRC105, a CD105 antibody, has been developed for PET imaging of angiogenesis in the mouse model of hind limb ischemia \[[@CR27]\]. The first serial imaging study evaluating ^64^Cu-TRC105 demonstrated peak radiotracer uptake at 3 and 10 days following femoral artery ligation, which was validated using histology and reverse transcription polymerase chain reaction (RT-PCR) of hind limb tissue. Further application of ^64^Cu-TRC105 has demonstrated the ability of this radiotracer to non-invasively track serial changes in angiogenesis following pravastatin therapy in the setting of hind limb ischemia and has showed significantly higher levels of radiotracer uptake in treatment vs. non-treatment groups \[[@CR34]\]. These findings suggest that non-invasive molecular imaging of peripheral angiogenesis may have potential for evaluating and monitoring serial responses to clinical treatment in patients with peripheral vascular disease.

Conclusions {#Sec5}
===========

Future translation of angiogenesis-targeted imaging with radiotracer-based approaches may advance evaluation of myocardial ischemia/infarction and peripheral vascular disease in the clinical setting. Additionally, molecular imaging of angiogenesis may allow for improved non-invasive assessment of serial responses to medical treatment, including revascularization, exercise training, and novel therapeutics. Ongoing SPECT and PET imaging studies targeted at the angiogenic process should focus on the development of radiotracers that will result in reasonable levels of ionizing radiation exposure for patients while also possessing high affinity for angiogenesis-related vascular targets, thereby facilitating clinical translational of molecular imaging approaches that should allow for integration of physiologic information with standard anatomic and clinical indices.
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